Company intelligence / Profile preview

Capillary Biomedical

Irvine, California, United Statestandemdiabetes.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Capillary Biomedical developed a novel extended-wear infusion set designed to improve the reliability and duration of insulin delivery for people with diabetes using pumps. The catheter design aimed to enable consistent absorption over seven or more days, reduce occlusions, and minimize body burden. As of its acquisition by Tandem Diabetes Care in July 2022, the product was still in development and not yet FDA approved or commercially launched[1][2][3].

Therapeutic areas: Endocrinology
Modalities: Device (specifically, infusion set for insulin delivery)
Industry: Consumable Medical Devices

Partnerships

Tandem Diabetes Care

Beyond the preview

Go deeper on Capillary Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capillary Biomedical.

Explore the full profile